DOP2013000182A - Inhibidores de catepsina c - Google Patents
Inhibidores de catepsina cInfo
- Publication number
- DOP2013000182A DOP2013000182A DO2013000182A DO2013000182A DOP2013000182A DO P2013000182 A DOP2013000182 A DO P2013000182A DO 2013000182 A DO2013000182 A DO 2013000182A DO 2013000182 A DO2013000182 A DO 2013000182A DO P2013000182 A DOP2013000182 A DO P2013000182A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- catepsin
- inhibitors
- butenamides
- amino
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se describen 4-amino-2-butenamidas de la Fórmula (l) que tienen actividad farmacológica, composiciones farmacéuticas que Ias contienen, y métodos para el tratamiento de enfermedades mediadas por la enzima catepsina C tales como la enfermedad pulmonar obstructiva crónica.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161441840P | 2011-02-11 | 2011-02-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2013000182A true DOP2013000182A (es) | 2014-03-16 |
Family
ID=46638952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2013000182A DOP2013000182A (es) | 2011-02-11 | 2013-08-09 | Inhibidores de catepsina c |
Country Status (23)
Country | Link |
---|---|
US (2) | US8841463B2 (es) |
EP (1) | EP2672821B9 (es) |
JP (1) | JP5931929B2 (es) |
KR (1) | KR20140048857A (es) |
CN (1) | CN103491777B (es) |
AR (1) | AR085163A1 (es) |
AU (1) | AU2012214405B2 (es) |
BR (1) | BR112013020510A2 (es) |
CA (1) | CA2827157A1 (es) |
CL (1) | CL2013002325A1 (es) |
CO (1) | CO6741219A2 (es) |
DO (1) | DOP2013000182A (es) |
EA (1) | EA023168B1 (es) |
ES (1) | ES2583091T3 (es) |
IL (1) | IL227814A0 (es) |
MA (1) | MA34961B1 (es) |
MX (1) | MX2013009279A (es) |
PE (1) | PE20140999A1 (es) |
SG (1) | SG192669A1 (es) |
TW (1) | TW201302736A (es) |
UY (1) | UY33905A (es) |
WO (1) | WO2012109415A1 (es) |
ZA (1) | ZA201306074B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014091443A1 (en) | 2012-12-13 | 2014-06-19 | Glaxo Group Limited | Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis |
NO2699580T3 (es) | 2014-01-24 | 2018-02-24 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2622581B1 (fr) * | 1987-11-03 | 1990-02-16 | Inorgan Sa Rech Develop Pharm | Nouveaux derives de l-proline, leur preparation et leurs applications biologiques |
CN1240355A (zh) * | 1996-05-01 | 2000-01-05 | 伊莱利利公司 | 蛋白激酶c抑制剂增强溶癌剂和放射治疗的临床功效的用途 |
US6232299B1 (en) | 1996-05-01 | 2001-05-15 | Eli Lilly And Company | Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy |
US6214799B1 (en) | 1996-05-14 | 2001-04-10 | Agouron Pharmaceuticals, Inc. | Antipicornaviral compounds and methods for their use and preparation |
AU2002232558A1 (en) * | 2000-12-12 | 2002-06-24 | Corvas International, Inc. | Compounds, compositions and methods for treatment of parasitic infections |
WO2008125945A2 (en) | 2007-04-12 | 2008-10-23 | Pfizer Inc. | 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c |
BRPI1015540A2 (pt) | 2009-05-07 | 2019-09-24 | Astrazeneca Ab | ''composto de 1-cianoetil-heterociclilcarboxamida substituídos 750'' |
UY32827A (es) | 2009-08-12 | 2011-02-28 | Glaxo Group Ltd | Inhibidores de catepsina c |
WO2012119941A1 (en) | 2011-03-04 | 2012-09-13 | Prozymex A/S | Peptidyl nitrilcompounds as peptidase inhibitors |
-
2012
- 2012-02-09 SG SG2013060165A patent/SG192669A1/en unknown
- 2012-02-09 KR KR1020137023618A patent/KR20140048857A/ko not_active Application Discontinuation
- 2012-02-09 ES ES12744272.1T patent/ES2583091T3/es active Active
- 2012-02-09 PE PE2013001836A patent/PE20140999A1/es not_active Application Discontinuation
- 2012-02-09 BR BR112013020510A patent/BR112013020510A2/pt not_active IP Right Cessation
- 2012-02-09 UY UY0001033905A patent/UY33905A/es unknown
- 2012-02-09 WO PCT/US2012/024428 patent/WO2012109415A1/en active Application Filing
- 2012-02-09 CN CN201280017698.7A patent/CN103491777B/zh not_active Expired - Fee Related
- 2012-02-09 US US13/984,061 patent/US8841463B2/en not_active Expired - Fee Related
- 2012-02-09 AU AU2012214405A patent/AU2012214405B2/en not_active Ceased
- 2012-02-09 TW TW101104141A patent/TW201302736A/zh unknown
- 2012-02-09 MX MX2013009279A patent/MX2013009279A/es not_active Application Discontinuation
- 2012-02-09 CA CA2827157A patent/CA2827157A1/en not_active Abandoned
- 2012-02-09 EA EA201391155A patent/EA023168B1/ru not_active IP Right Cessation
- 2012-02-09 MA MA36229A patent/MA34961B1/fr unknown
- 2012-02-09 EP EP12744272.1A patent/EP2672821B9/en active Active
- 2012-02-09 JP JP2013553538A patent/JP5931929B2/ja not_active Expired - Fee Related
- 2012-02-10 AR ARP120100455A patent/AR085163A1/es unknown
-
2013
- 2013-08-05 IL IL227814A patent/IL227814A0/en unknown
- 2013-08-09 DO DO2013000182A patent/DOP2013000182A/es unknown
- 2013-08-09 CL CL2013002325A patent/CL2013002325A1/es unknown
- 2013-08-09 CO CO13190045A patent/CO6741219A2/es unknown
- 2013-08-13 ZA ZA2013/06074A patent/ZA201306074B/en unknown
-
2014
- 2014-08-21 US US14/464,734 patent/US9187461B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
IL227814A0 (en) | 2013-09-30 |
EP2672821B1 (en) | 2016-04-20 |
JP2014506577A (ja) | 2014-03-17 |
AU2012214405B2 (en) | 2015-07-23 |
AR085163A1 (es) | 2013-09-11 |
JP5931929B2 (ja) | 2016-06-08 |
US8841463B2 (en) | 2014-09-23 |
US20130324584A1 (en) | 2013-12-05 |
BR112013020510A2 (pt) | 2016-07-12 |
AU2012214405A1 (en) | 2013-04-18 |
SG192669A1 (en) | 2013-09-30 |
MX2013009279A (es) | 2013-10-28 |
NZ614540A (en) | 2015-03-27 |
EP2672821B9 (en) | 2016-11-23 |
UY33905A (es) | 2012-08-31 |
WO2012109415A1 (en) | 2012-08-16 |
PE20140999A1 (es) | 2014-09-11 |
CA2827157A1 (en) | 2012-08-16 |
CO6741219A2 (es) | 2013-08-30 |
KR20140048857A (ko) | 2014-04-24 |
MA34961B1 (fr) | 2014-03-01 |
EA023168B1 (ru) | 2016-04-29 |
ZA201306074B (en) | 2014-04-30 |
ES2583091T3 (es) | 2016-09-19 |
EA201391155A1 (ru) | 2014-01-30 |
US20140364476A1 (en) | 2014-12-11 |
CN103491777A (zh) | 2014-01-01 |
EP2672821A4 (en) | 2014-08-06 |
EP2672821A1 (en) | 2013-12-18 |
TW201302736A (zh) | 2013-01-16 |
CN103491777B (zh) | 2015-05-06 |
CL2013002325A1 (es) | 2014-01-03 |
US9187461B2 (en) | 2015-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018236800B2 (en) | DNA-PK inhibitors | |
DOP2016000175A (es) | (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
BR112014002202A2 (pt) | macrociclos como inibidores de fator xia | |
CL2013001340A1 (es) | Compuestos derivados de isoindol-amida, pirrolo-piridin-amida y pirrolo-pirimimidin-amida, inhibidores de nampt y rock; composicion farmaceutica; y metodo para tratar hiperetension, insuficiencia cardiaca cronica, aterosclerosis, asma, enfermedad de alzheimer, enfermedad de parkinson y glaucoma, entre otras enfermedades. | |
CO6551666A2 (es) | Macrociclos como inhibidores del factor de coagulacion (fxia) | |
PE20121617A1 (es) | Derivados de oxazina como inhibidores de bace | |
GT201400016A (es) | Indazoles | |
EA201391719A1 (ru) | Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
CR20130588A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2 | |
CL2016001543A1 (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas. | |
BR112015000704A2 (pt) | imidazotriazinacarbonitrilas úteis como inibidores de quinase | |
EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
BR112013001753A2 (pt) | método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada. | |
EA201491028A1 (ru) | Способ получения замещенных 5-фтор-1н-пиразолопиридинов | |
EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
WO2013052943A3 (en) | Small molecule inhibitors of mcl-1 and uses thereof | |
CU20140072A7 (es) | Derivados de dihidro-oxazina y dihidro-pirido-oxazina | |
PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
MX2011009847A (es) | Agentes antihelminticos y su uso. | |
BR112014012459A2 (pt) | 2h-indazóis como antagonistas do receptor de ep2 | |
PE20141944A1 (es) | N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilacetidina-1-sulfonamida como moduladores del receptor de quimiocina | |
BR112017000584A2 (pt) | inibidores da aldosterona sintase | |
BR112014012892A2 (pt) | agentes de reversão anticoagulantes | |
DOP2013000182A (es) | Inhibidores de catepsina c |